Who are The midazolam ketamine group's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/the-midazolam-ketamine-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

The midazolam ketamine group — Competitive Intelligence Brief

The midazolam ketamine group (The midazolam ketamine group) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Benzodiazepine and NMDA receptor antagonist. Area: Anesthesiology.

phase 3 Benzodiazepine and NMDA receptor antagonist GABA_A receptor, NMDA receptor Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

The midazolam ketamine group (The midazolam ketamine group) — Kasr El Aini Hospital. Midazolam is a benzodiazepine that acts as a GABA_A receptor agonist, while ketamine is an NMDA receptor antagonist.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
The midazolam ketamine group TARGET	The midazolam ketamine group	Kasr El Aini Hospital	phase 3	Benzodiazepine and NMDA receptor antagonist	GABA_A receptor, NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Benzodiazepine and NMDA receptor antagonist class)

Kasr El Aini Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). The midazolam ketamine group — Competitive Intelligence Brief. https://druglandscape.com/ci/the-midazolam-ketamine-group. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab